Night For Knox 2026

Welcome to Night For Knox, KMF's biggest night of the year! Every year since our inception, we've hosted 300 guests for an elevated fundraising gala called the Night For Knox. On February 7th, 2026, we will once again host a beautiful seated dinner, a live auction, and a musical performance to close out the night at the Atlanta Athletic Club.

KMF has given $1.5M to the Duke Brain Tumor Center, supporting 5 landmark projects on high grade glioma and glioblastoma since 2021. Collectively, these projects show how the generosity of our donors fuels progress across the entire spectrum of brain tumor research—from discovery to direct patient impact.

The majority of our funds are raised at Night For Knox each year. With your help, we are funding the next breakthrough in brain cancer research, one clinical trial at a time!

Learn more about what we do or read below.

We are so proud to announce that the Knox Martin Foundation for Brain Cancer Research was selected to receive the prestigious William W. Shingleton Award from the Duke Cancer Institute (DCI) at Duke University on October 23rd, 2025.

The award, presented by DCI’s Shingleton Society, recognizes exemplary generosity, service, and dedication to advancing cancer research, care, and patient-support initiatives. The Shingleton Society recognizes donors and partners who give at significant levels and who engage their time and resources to further DCI’s mission of extending and improving the lives of people with cancer.

KMF has given $1.5M to the Duke Brain Tumor Center, supporting 5 landmark projects on high grade glioma and glioblastoma since 2021. Collectively, these projects show how the generosity of our donors fuels progress across the entire spectrum of brain tumor research—from discovery to direct patient impact.

1. PESKE Trial – Now completed and closed, results have been published. You can read them here!
2. FLIRT Trial with Fluoxetine – Now completed and closed, with manuscripts expected within the coming year
   
3. TIL Development – Preclinical efforts are advancing to prepare the next wave of IND-enabling studies
4. Personalized Vaccine Program – Functional validation is underway as our lab moves toward IND submission and first-in-human testing
5. MOAB Trial – A multicenter trial of atezolizumab in recurrent glioblastoma, now open at Duke, Kansas City, Huntsman Cancer Center in Utah, and UCSF. So far, 29 patients have already enrolled, and KMF support is enabling deep analysis of their samples
   

These initiatives span the full continuum: from completed trials moving toward publication, to cutting-edge preclinical innovation, to an ongoing trial already making a difference for patients. Our support is the bridge that sustains these efforts with our lab team at the Duke Brain Tumor Center and accelerates discoveries that would otherwise not be possible.

With the help of our donors, we are truly advancing research on brain cancer to give warriors like Knox a shot at a long life! Please consider joining us in 2026 as we strive to continue funding this important and vital research at the Duke Brain Tumor Center

Coming from out of town? Book a room at The Hotel Avalon or The Courtyard Atlanta/Alpharetta Avalon Area

The Hotel Avalon: 9000 Avalon Boulevard; Alpharetta, GA 30009

The Courtyard Atlanta/Alpharetta Avalon Area: 11700 Amber Park Drive; Alpharetta, Georgia, USA, 30009

(Both hotels are approximately 20 minutes from the Atlanta Athletic Club)